Key result
BNP remains a valid HF biomarker for diagnosis and prognosis despite mild early ARNI-induced increases.
Why the study?
It was unclear whether BNP remains a valid biomarker for heart failure diagnosis, pathophysiology, and prognosis in the angiotensin receptor/neprilysin inhibitor era.
Answers are grounded in this paper and cite their sources.
Despite early mild increases due to neprilysin inhibition, BNP remains a valid biomarker for heart failure diagnosis and prognosis in patients treated with ARNI.
Myocardial wall stress, cytokines, hormones, and ischemia all stimulate B-type (or brain) natriuretic peptide (BNP) gene expression. Within the myocardium, ProBNP-108, a BNP precursor, undergoes glycosylation, after which a portion is cleaved by furin into mature BNP-32 and N-terminal proBNP-76, depending on the glycosylation status. As a result, active BNP, less active proBNP, and inactive N-terminal proBNP all circulate in the blood. There are three major pathways for BNP clearance: (1) cellular internalization via natriuretic peptide receptor (NPR)-A and NPR-C; (2) degradation by proteases in the blood, including neprilysin, dipeptidyl-peptidase-IV, insulin degrading enzyme, etc.; and (3) excretion in the urine. Because neprilysin has lower substrate specificity for BNP than atrial natriuretic peptide (ANP), the increase in plasma BNP after angiotensin receptor neprilysin inhibitor (ARNI) administration is much smaller than the increase in plasma ANP. Currently available BNP immunoassays react with both mature BNP and proBNP. Therefore, BNP measured with an immunoassay is mature BNP + proBNP. ARNI administration increases mature BNP but not proBNP, as the latter is not degraded by neprilysin. Consequently, measured plasma BNP initially increases with ARNI administration by the amount of the increase in mature BNP. Later, ARNI reduces myocardial wall stress, and the resultant reduction in BNP production more than offsets the increase in mature BNP mediated by inhibiting degradation by neprilysin, which lowers plasma BNP levels. These results suggest that even in the ARNI era, BNP can be used for diagnosis and assessment of the pathophysiology and prognosis of heart failure, though the mild increases early during ARNI administration should be taken into consideration.
No takes yet. Share an insight, caveat, or question.
Nishikimi et al. (2022) conducted a review in Heart failure. Angiotensin receptor neprilysin inhibitor (ARNI) was evaluated. B-type natriuretic peptide (BNP) remains a valid biomarker for the diagnosis and prognosis of heart failure in the ARNI era, despite mild initial increases during early ARNI administration.
Synapse has enriched 10 related papers. Consider them for comparative context: